Chemotherapy Agents

Phase 2Small molecule

Takeda

Chemotherapy Agents is one of 147 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

146

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Systemic SclerosisActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Systemic SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Chemotherapy Agents

Takeda

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

PEG-Intron

Merck & Co.

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2038

Phase 2Active, not recruiting

Lymphoma

NCT05020015

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT05886491·16 enrolled

Lymphoma1 trial

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting· Takeda logo

Takeda·Phase 2·NCT05020015·27 enrolled

Pancreatic Cancer1 trial

Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?

Completed·KKochi University··NCT06921252·276 enrolled

Acute Lymphoblastic Leukemia1 trial

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Terminated· Takeda logo

Takeda·Phase 1/2·NCT04501614·11 enrolled

Systemic Sclerosis1 trial

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

Withdrawn· Takeda logo

Takeda·Phase 1·NCT06377228

1 more indication

Unspecified1 trial

Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease

Unknown status·NNational Taiwan University Hospital··NCT00166790·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Chemotherapy Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chemotherapy Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chemotherapy Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

Chemotherapy Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2038

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Lymphoma1 trial

Pancreatic Cancer1 trial

Acute Lymphoblastic Leukemia1 trial

Systemic Sclerosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News